Navigation Links
Beyond PTEN: Alternate genes linked to breast, thyroid and kidney cancer predisposition
Date:8/7/2008

A new discovery may lead to more effective screening and treatment for patients with a difficult to recognize syndrome characterized by tumor-like growths and a high risk of developing specific cancers. The research, published by Cell Press in the August 7 issue of the American Journal of Human Genetics, is the first in over thirteen years to identify an alternate susceptibility gene for Cowden syndrome (CS) and related disorders.

Mutations of the common tumor suppressor PTEN are associated with most cases of CS, a poorly recognized, inherited cancer syndrome that causes benign and malignant breast, thyroid and uterine tumors. However, about 15% of CS patients do not exhibit PTEN mutations and the cause for the disorder in these patients is unknown. Further, many patients present with a poorly understood CS-like syndromes that do not meet the diagnostic guidelines for CS. "Other susceptibility genes for CS and CS-like phenotypes must exist," says lead study author Dr. Charis Eng, the Hardis Chair and Director of the Genomic Medicine Institute at the Cleveland Clinic.

Succinate dehydrogenase (SDH) is a mitochondrial enzyme that is responsible for energy production and is therefore vital to all organs and organisms. Mutations in both copies of the SDH genes cause a rare devastating brain and heart condition resulting in death in infancy and childhood. Surprisingly, mutations in one of the pair of genes for various forms of SDH (referred to as SDHx) have been linked to a group of rare tumors called paragangliomas and pheochromocytomas. Dr. Eng noticed, however, that 1-5% of individuals with these rare tumors also had thyroid cancers similar to those observed in CS and CS-like patients. "We hypothesized that SDHx might represent susceptibility genes, other than PTEN, for CS/CS-like syndromes," explains Dr. Eng.

Dr. Eng and colleagues screened samples from CS/CS-like individuals that did not possess PTEN mutations for mitochondrial dysfunction. They identified a subset of patients with CS or CS-like syndrome that had various SDH mutations that were unrelated to PTEN mutations. Compared with PTEN mutation positive CS/CS-like individuals, those with SDH mutations exhibited a consistently increased risk for breast, thyroid and kidney cancers. Interestingly, in the absence of PTEN alteration, CS/CS-like-related SDH mutations exhibited perturbations of cellular signaling pathways similar to those seen in PTEN dysfunction.

"Our data have important implications for both patient care and genetic counseling. I would like to see others independently repeat our observations. Nonetheless, clinicians should consider SDH testing for PTEN mutation-negative CS/CS-like individuals, especially if these individuals have a strong personal history and/or family history of breast, thyroid or kidney cancer. In fact, patients with SDHx mutation should be more rigorously screened for these cancers compared to those with PTEN mutations," concludes Dr. Eng.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. New Anti-Cellulite Treatment Prepares Women for Warmer Weather and Beyond
2. Lou Gehrigs protein found throughout brain, suggesting effects beyond motor neurons
3. Haemacure Raises $7.8 Million and is Fully Funded Beyond First-Patient-In-Clinic
4. New KLRI Reports Shows Longevity Science Moving Beyond Studying the Obvious to the Downward Spiral Paradigm in the Aging Process
5. PointOne Launches New Business Direction, Healthcare Analytics Beyond Hospitals
6. Beyond Traditional Borders sends more Rice U. undergrads to Africa
7. Beyond nutrition -- plants deliver
8. Beyond Off-shoring and Out-sourcing: Supply Chain Imperatives
9. Beyond the terminal: Palliative care
10. BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond
11. VisionFirst to Create Birminghams Next Reality Star with Beyond the Big E Contest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... 21, 2017 , ... The American Hospital Association (AHA) has elected Claire Zangerle, ... to its Board of Trustees for a three-year term beginning January 1, 2018. ... and individuals that are committed to the improvement of health in their communities. Founded ...
(Date:8/20/2017)... ... August 20, 2017 , ... HIPAA ... Management System has assisted multiple clients in successfully passing audits such as ... Control Level 2 (AICPA SOC Level 2), and State Data Use Agreement Audits. ...
(Date:8/19/2017)... ... August 18, 2017 , ... Paragon and ... to help the cannabis industry move towards greater legitimacy. By incorporating IOTA’s unique ... technology with lower fees. Paragon will build a fully verifiable database to track ...
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... Yesterday, the ... KKK by saying there are two sides. There are not two sides to hatred, ... to rationalize violence and prejudice, and the NPEIV stands against all forms of such ...
(Date:8/18/2017)... , ... August 18, 2017 , ... More than 20,000 ... Republic of Congo (DRC) thanks to an ambitious venture that conjoined the passions of ... the generous support of the Liberty community. These shoes will save lives from the ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
(Date:7/27/2017)... July 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... for the second-quarter 2017 and updated financial guidance for ... Second-Quarter 2017 Highlights Reported net sales ... the prior-year quarter. Net sales at constant currency (organic) ... EPS was $0.51, compared to $0.60 in the prior-year ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
Breaking Medicine Technology: